Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial

Creative Commons License

Solomon S. D., Claggett B., Desai A. S., Packer M., Zile M., Swedberg K., ...Daha Fazla

CIRCULATION-HEART FAILURE, cilt.9, sa.3, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1161/circheartfailure.115.002744
  • Dergi Adı: CIRCULATION-HEART FAILURE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: heart, heart failure, humans, mineralocorticoid receptor antagonists, neprilysin, INHIBITION, ENALAPRIL
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with enalapril in patients with heart failure (HF) and reduced ejection fraction (EF) in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. We evaluated the influence of EF on clinical outcomes and on the effectiveness of sacubitril/valsartan compared with enalapril.